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the most common diseases in Poland. Only 13% of those
affected currently receive any kind of treatment. This is
the first study in Poland with the intention of demon-
strating the cost of CVI.
METHODS: A representative group of 1000 people over
18 years old was randomised, and 223 treated patients
were questioned by an external agency *. All the data
were collected with the help of a special resource utilisa-
tion questionnaire. Items measured included oral drugs,
topical drugs, compression therapy, surgical and cos-
metic interventions (sclerotherapy, operational proce-
dures), diagnostic tests (including Doppler investigation)
and hospitalizations. The value of social and family help,
sick leave and early retirement due to CVI were also esti-
mated (capital cost method).
RESULTS: The average total cost per person per year
from the study group was 952,94 PLN (1 EURO 
3,4517 PLN) with average direct costs of 233,39 PLN
and average indirect costs of 719,54. The total burden of
CVI in Poland in terms of direct medical costs may reach
6.5 billion PLN (24% of the total cost). The distribution
of total costs per person in the investigated group is as
follows: oral treatment, 37,93 PLN (4%); local treatment
(ointments, gels, creams), 26,15 PLN (3%); compression
therapy 11,52 PLN (1%); all surgical interventions 46,84
PLN (5%); hospitalisations (all wards) 110,95 PLN
(12%); family and social help 466,50 PLN (49%); sick
leave 108,15 PLN (11%); pensions 144,90 (15%).
CONCLUSION: CVI represents an important economic
burden for the Polish population. Among direct medical
costs, oral treatment and compression constitute only
21%, while the cost of hospitalisation accounts for 48%.
An early diagnosis, proper treatment and management of
CVI leading to an optimal allocation of expenditures may
contribute to a significant reduction of the total costs of
CVI in Poland.
* PENTOR - Medical - Institute for Opinion and Market
Research.
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OBJECTIVE: To investigate and quantify the impact on
total treatment costs of cardiovascular disease associated
with the use of amlodipine in patients with coronary ar-
tery disease (CAD) in the United Kingdom.
METHODS: A Markov cohort simulation model was de-
veloped to estimate the expected health outcomes and
costs of CAD cohorts on amlodipine versus placebo over
three years. Clinical outcomes included in the analysis
were: hospitalization for angina; hospitalization for MI;
hospitalization for congestive heart failure (CHF); PTCA;
CABG; various combinations of these events and proce-
dure-related outcomes, and death. Transitional probabili-
ties used in the model were based on patient-level data
from the Prospective Evaluation of the Vascular Effects
of Norvasc Trial (PREVENT). Health outcomes were dis-
counted at a rate of 1.5% and all costs were discounted
at a rate of 6%.
RESULTS: The amlodipine cohort experienced fewer
hospitalizations due to angina, CABG, PTCA, CHF, and
MI than the placebo cohort did. The rate of hospitaliza-
tion per patient in the placebo cohort was 61.8% while
that in the amlodipine cohort was 44.3%. The cost per
patient for treatment of CVD was £1,859 for amlodipine
patients and £1,800 for placebo patients over three years
of follow-up. For amlodipine use this equates to an incre-
mental cost per hospitalization avoided of £332.
CONCLUSION: In the UK, the use of amlodipine re-
sulted in improved clinical outcomes through a marginal
investment in cost.
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OBJECTIVE: To generate estimates of the cost-effective-
ness of thromboprophylaxis with enoxaparin versus no
thromboprophylaxis (usual care) in patients with acute
medical illness in the health-care setting of Italy from the
NHS perspective.
METHODS: Markov process analysis techniques were
used to model the health-economic outcomes. Data col-
lection was based on probabilities of clinical events from
clinical trial data from the MEDENOX trial and other
published literature, OECD country-specific general pop-
ulation mortality and Delphi panels. Units of health-care
utilization were derived from the Delphi panels. Prices
and tariffs were derived from official lists.
RESULTS: Analysis over one year showed that the cost
per venous thromboembolic (VTE) event avoided was
Lit4.500.586 (EURO 2324) and cost per life saved was
Lit16.042.624 (EURO8285), when assuming no higher
risk for morbidity and mortality for asymptomatic pa-
tients. The lifetime model (again, assuming no higher risk
for recurrence of VTE in asymptomatic patients), showed
that enoxaparin increased the total costs from Lit804.900
(EURO416) to Lit1.180.000 (EURO609), while the life ex-
pectancy increased from 14.11 to 14.43 years. Consequently,
cost per life year gained was Lit1.172.188 (EURO605),
and the cost per event avoided was Lit4.343.446
(EURO2.243).
CONCLUSION: The results showed that the favorable
clinical benefit of enoxaparin observed in MEDENOX
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also resulted in a positive short- and long-term health
economic benefit in acutely ill medical patients. The
health-economic benefit of enoxaparin was positively re-
lated with the length of the follow-up period and a higher
risk for recurrence of VTE and mortality in asymptom-
atic patients.
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The post-thrombotic syndrome (PTS) is a serious long-
term complication of deep-vein thrombosis (DVT) that
may only be avoided by preventing the initial DVT. No
pharmacoeconomic assessment of low molecular weight
heparin (LMWH) has included the impact of reducing
these long-term complications in the UK.
OBJECTIVES: To determine the cost effectiveness of
LMWH (enoxaparin, 7 days, 40 mg daily) versus unfrac-
tionated heparin (UFH, 7 days, 15,000 units daily) for
the universal prophylaxis of DVT and PTS in patients un-
dergoing total hip replacement surgery (THRS).
METHODS: A probabilistic health-state transition model
using a Monte-Carlo (MC) simulation was developed to
project the long-term cost-effectiveness of the two strate-
gies in a cohort of 10,000 patients. The risk of develop-
ing a DVT in the short term (i.e., two weeks) was esti-
mated using epidemiological and clinical trial data. Patients
who survived a DVT in the short term were exposed to
the long-term risk of PTS and recurrent VTE whereas
other surviving patients were only exposed to the long-
term risk of idiopathic PTS and VTE. Economic literature
and expert opinion served as input for the model’s re-
source use and costs for DVT prophylaxis, clinical diag-
nosis and treatment of DVT, PE, and PTS. Five thousand
MC simulations were run on the model.
RESULTS: In the baseline, point-estimate analysis, LMWH
use prevented 240 DVTs and 13 deaths in the short term
compared to UFH, and resulted in net savings of £10 per
patient. In the long term, LMWH saved an additional
£36 in DVT complication costs. LMWH was the domi-
nant strategy in 70% of cases and was cost-effective in
72% overall.
CONCLUSION: This is the first economic analysis com-
paring LMWH and UFH that includes the long-term
complications of DVT. Our model indicates that the in-
clusion of these long-term complications supports the
widespread use of LMWH in patients undergoing THRS.
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OBJECTIVE: To estimate the cost-effectiveness of carvedilol
relative to bisoprolol as adjunctive beta blocker (BB) ther-
apy in patients with chronic heart failure.
METHODS: Comparison of survival benefits was per-
formed using the CIBIS-II placebo group as a representa-
tive cohort not treated with a BB. Using parametric sur-
vival analysis, five-year survival estimates were calculated
for bisoprolol and carvedilol based on published data for
the major mortality studies of the two BBs with similar
placebo mortality risks (CIBIS-II (hazard ratio 0.66) and
US Carvedilol Trial Program (hazard ratio 0.35)). Lim-
ited and extended benefit scenarios were estimated under
varying assumptions about the sustainability of BB treat-
ment effect. Under the limited benefits scenario the treat-
ment effect was conservatively assumed to last only until
the end of the reported trial periods. The extended bene-
fits scenario was assumed to persist up to five years. Tak-
ing the perspective of the UK NHS we estimated differ-
ences in treatment costs (medication, outpatient/GP visits,
hospitalization), and absolute mortality benefits to form
an incremental cost-effectiveness ratio.
RESULTS: The estimated benefit per patient at five years
under the extended benefits scenario was 145 days (0.398
yr.) for bisoprolol and 301 days (0.823 yr.) for carvedilol.
The corresponding figures for the limited benefits scenario
are 93 days (0.254 yr.) for bisoprolol and 119 days (0.325
yr.) for carvedilol. Over five years the estimated incremen-
tal cost-effectiveness ratio of carvedilol compared to biso-
prolol is £5,900 per LYG under limited and £1,800 per
LYG under extended benefit scenarios respectively.
CONCLUSIONS: Carvedilol represents a cost-effective
adjunctive treatment compared to bisoprolol in patients
with chronic heart failure. Statistical extrapolation indi-
cates that the relatively greater mortality benefits associ-
ated with carvedilol relative to bisoprolol are accrued at a
cost, which compares favourably with that of many other
common cardiovascular treatments such as statins and
ACE inhibitors.
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OBJECTIVE: The goal of this study is to evaluate and
determine the cost-effectiveness (CE) of a college of phar-
macy’s tobacco outreach program targeting thirteen- to
